First Trust Direct Indexing L.P. Purchases 2,571 Shares of DexCom, Inc. (NASDAQ:DXCM)

First Trust Direct Indexing L.P. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 25.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,491 shares of the medical device company’s stock after acquiring an additional 2,571 shares during the period. First Trust Direct Indexing L.P.’s holdings in DexCom were worth $1,733,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of DXCM. Capital World Investors boosted its stake in DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after buying an additional 5,256,092 shares during the period. Norges Bank purchased a new position in shares of DexCom during the fourth quarter worth about $540,178,000. Artisan Partners Limited Partnership increased its position in shares of DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Capital Research Global Investors raised its stake in DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new stake in DexCom during the fourth quarter valued at approximately $231,773,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the sale, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other DexCom news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the sale, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders sold a total of 55,735 shares of company stock valued at $7,619,347 in the last quarter. 0.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on DXCM. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Redburn Atlantic initiated coverage on DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target for the company. Citigroup increased their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Raymond James boosted their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Finally, Canaccord Genuity Group increased their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $140.33.

DexCom Stock Performance

Shares of DXCM stock opened at $110.91 on Friday. The firm has a market capitalization of $44.11 billion, a price-to-earnings ratio of 71.56, a PEG ratio of 2.71 and a beta of 1.16. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The stock has a fifty day moving average of $121.24 and a 200 day moving average of $125.37.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, research analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.